Dublin, Dec. 23, 2020 (GLOBE NEWSWIRE) -- The "Cancer Pain - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
Cancer Pain - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Cancer Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cancer Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cancer Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 6, 7, 7, 1, 15, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Cancer Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
The pipeline guide provides a snapshot of the global therapeutic landscape of Cancer Pain (Central Nervous System).
The pipeline guide reviews pipeline therapeutics for Cancer Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Cancer Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Cancer Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Cancer Pain (Central Nervous System)
Key Topics Covered:
Cancer Pain - Overview
Cancer Pain - Therapeutics Development
Cancer Pain - Therapeutics Assessment
Cancer Pain - Companies Involved in Therapeutics Development
Cancer Pain - Drug Profiles
Cancer Pain - Dormant Projects
Cancer Pain - Discontinued Products
Cancer Pain - Product Development Milestones
Alexza Pharmaceuticals Inc
Aquilus Pharmaceuticals Inc
Beckley Canopy Therapeutics Ltd
Cassava Sciences Inc
Concentric Analgesics Inc
Dompe Farmaceutici SpA
Fujimoto Pharmaceutical Corp
Hisamitsu Pharmaceutical Co Inc
Intec Pharma Ltd
iX Biopharma Ltd
Jiangsu Huatai Chenguang Pharmaceutical Co Ltd
Klaria Pharma Holding AB
Komipharm International Co Ltd
Luye Pharma Group Ltd
Medlab Clinical Ltd
Mundipharma International Ltd
Neurocentrx Pharma Ltd
Nippon Zoki Pharmaceutical Co Ltd
Park Therapeutics Inc
Sedor Pharmaceuticals LLC
Sorrento Therapeutics Inc
Tetra Bio-Pharma Inc
WEX Pharmaceuticals Inc
Winston Pharmaceuticals Inc
Yichang Renfu Pharmaceutical Co Ltd
Yongzhan International Pharmaceutical Co Ltd
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/12lscy
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900